Zimmer Biomet (ZBH)
(Delayed Data from NYSE)
$105.46 USD
+0.86 (0.82%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $105.48 +0.02 (0.02%) 7:58 PM ET
4-Sell of 5 4
B Value C Growth F Momentum C VGM
Price, Consensus and EPS Surprise
ZBH 105.46 +0.86(0.82%)
Will ZBH be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for ZBH based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ZBH
ZBH Gears Up for Q3 Earnings: What Lies Ahead for the Stock?
SNN Boosts Knee Revision Surgery With Its LEGION Hinged Knee System
ZBH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Is Zimmer (ZBH) Down 3.9% Since Last Earnings Report?
Should You Consider Retaining ZBH Stock in Your Portfolio Now?
Market Share Gains Aid Zimmer Biomet Stock Amid Cost Pressure
Other News for ZBH
McDonald's To Rally Around 13%? Here Are 10 Top Analyst Forecasts For Tuesday
Johnson & Johnson reported strong earnings beat, says Barclays
Zimmer Biomet price target lowered by $10 at Oppenheimer, here's why
Eight stocks positioned for short sales – Oppenheimer Asset Management
Zimmer Biomet price target lowered by $5 at Raymond James, here's why